Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Work in process Inventory, Work in Process, Gross Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Potential commercial milestone payments under agreement PotentialCommercialMilestonePaymentsUnderAgreement Income Statement Location [Axis] Income Statement Location [Axis] Range [Domain] Statistical Measurement [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Restricted Stock Units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Potential proceeds from royalties (percent) ProceedsfromRoyaltiesPercent U.S. Treasury securities US Treasury Securities [Member] Income Statement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Shares, Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Asset Class [Domain] Asset Class [Domain] NIAID NationalInstituteOfAllergyAndInfectiousDiseasesMember Other non current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Cash received for options exercised Proceeds from Stock Options Exercised Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Non-refundable upfront payment, net of tax withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Weighted- Average Exercise Price, Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Available-for-sale Marketable Securities Debt Securities, Available-for-sale [Table Text Block] Fair Value Disclosures [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventory, net Total inventory, net Inventory, Net Shares, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Organization, Consolidation and Presentation of Financial Statements [Abstract] Incyte MGA012 Supply Agreement Incyte MGA012 Supply Agreement [Member] Incyte MGA012 Supply Agreement Incyte MGA012 Agreement IncyteMGA012AgreementMember Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Weighted- Average Exercise Price, Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Research and Development Research and Development Expense [Member] Product and Service [Axis] Product and Service [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Total unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Award Type [Domain] Award Type [Domain] Common stock purchased (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period RevenuesFromCMOAgreementsMember RevenuesFromCMOAgreementsMember [Member] RevenuesFromCMOAgreementsMember Local Phone Number Local Phone Number Assets Assets [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Shares, Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Statement [Line Items] Statement [Line Items] Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Other non current liabilities Increase (Decrease) in Other Current Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Schedule of Stock Options Roll Forward Schedule of Stock Options Roll Forward [Table Text Block] Non-refundable upfront payment NonRefundableUpfrontFees Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Marketable securities Investments Options outstanding (in shares) Shares, Outstanding, Beginning Balance (in shares) Shares, Outstanding, Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Securities Fair Value Debt Securities, Available-for-sale Accumulated Deficit Retained Earnings [Member] Counterparty Name [Domain] Counterparty Name [Domain] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Purchase price of common stock percent of the fair market value Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Level 2 Fair Value, Inputs, Level 2 [Member] Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Proceeds from stock option exercises ProceedsfromStockOptionsExercisedAndESPPPurchases Janssen Biotech Inc Janssen Biotech Inc [Member] Janssen Biotech Inc Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Incyte MGA012 Agreement - Clinical activities IncyteMGA012AgreementClinicalActivitiesMember Maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance Accounts receivable Increase (Decrease) in Accounts Receivable Property, equipment and software included in accounts payable or accruals Capital Expenditures Incurred but Not yet Paid Incyte MGA012 Clinical Services Incyte MGA012 Clinical Services [Member] Incyte MGA012 Clinical Services Asset Class [Axis] Asset Class [Axis] Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Total assets Assets Stock plan activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Basic net loss per common share (in usd per share) Earnings Per Share, Basic Document Type Document Type Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Beginning Balance (in shares) Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Potential development and regulatory milestone payments under agreement PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement At the Market Offering At The Market Offering [Member] At The Market Offering Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Premium received on stock purchase PremiumReceivedOnStockPurchase PremiumReceivedOnStockPurchase Nonrefundable payment tax withholding Nonrefundable Payment Tax Withholding Nonrefundable Payment Tax Withholding Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Share-based compensation, number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted net loss per common share (in usd per share) Earnings Per Share, Diluted Offering period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Sales of stock purchase price (in dollars per share) Sale of Stock, Price Per Share Product revenue, net Product [Member] Estimated variable consideration Revenue, Information Used To Assess Variable Consideration, Amount Revenue, Information Used To Assess Variable Consideration, Amount Fair value of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Revenue from collaborative and other agreements RevenueFromCollaborativeAgreementsMember Plan Name [Axis] Plan Name [Axis] Zai Lab Clinical Supply Agreements Zai Lab Clinical Supply Agreements [Member] Zai Lab Clinical Supply Agreements Assets: Assets, Fair Value Disclosure [Abstract] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred revenue Contract with Customer, Liability Total assets measured at fair value Assets, Fair Value Disclosure Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Zai Lab Agreement, TRIDENT molecule Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member] Zai Labs Collaboration And License Agreement, TRIDENT molecule Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Entity Small Business Entity Small Business Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Total liabilities and stockholders' equity Liabilities and Equity Investments, Debt and Equity Securities [Abstract] Schedule of RSU Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Corporate debt securities Corporate Debt Securities [Member] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current Revenue Collaboration And Other Agreements Disclosure [Text Block] Proceeds from sale and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Accounts payable Accounts Payable, Current Weighted- Average Exercise Price, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Depreciation and amortization expense Depreciation, Depletion and Amortization I-Mab Biopharma Collaboration And License Agreement Clinical Supply I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member] I-Mab Biopharma Collaboration And License Agreement Clinical Supply Liabilities and stockholders' equity Liabilities and Equity [Abstract] Development and regulatory milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Potential milestone payments and royalties on product sales Potential Milestone Payments and Royalties On Product Sales Potential Milestone Payments and Royalties On Product Sales Inventory Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Zai Lab Agreement, Margetuximab Zai Labs Collaboration And License Agreement, Margetuximab [Member] Zai Labs Collaboration And License Agreement, Margetuximab Financial Instruments [Domain] Financial Instruments [Domain] Entity Interactive Data Current Entity Interactive Data Current Cost of product sales Cost of Goods and Services Sold Revenues: Revenues [Abstract] Minimum Minimum [Member] Document Period End Date Document Period End Date 2018 Zai Lab Agreement 2018 Zai Lab Collaboration And License Agreement [Member] 2018 Zai Lab Collaboration And License Agreement 2016 Employee Stock Purchase Plan TwoThousandSixteenEmployeeStockPurchasePlanMember Entity Central Index Key Entity Central Index Key Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares per employee Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] One Time Millstone Credit One Time Millstone Credit One Time Millstone Credit Income Statement Location [Domain] Income Statement Location [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province Incyte Corporation IncyteCorporationMember Revenues, net of tax withholding Revenues, Net Of Tax Withholding Revenues, Net Of Tax Withholding Property, equipment and software, net Property, Plant and Equipment, Net Accumulated Other Comprehensive Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Other non current liabilities Other Liabilities, Noncurrent Current liabilities: Liabilities, Current [Abstract] Revenues From Grants RevenuesFromGrantsMember Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Lease liabilities Increase (Decrease) in Operating Lease Liability Selling, general and administrative General and Administrative Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Potential annual increase in shares reserved for future issuance as percentage of outstanding share PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan Trading Symbol Trading Symbol Weighted- Average Exercise Price, Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock-Based Compensation Share-based Payment Arrangement [Text Block] Payroll deduction percentage EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent Inventory, Net Inventory Disclosure [Text Block] Accounting Policies [Abstract] Other non current assets Increase (Decrease) in Other Operating Assets Revenues Revenues Weighted- Average Remaining Contractual Term, Outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Janssen Collaboration and License Agreement Janssen Collaboration And License Agreement [Member] Janssen Collaboration And License Agreement Accumulated other comprehensive loss AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax Issuance of common stock, net of offering costs (in shares) Number of shares issued or sold (in shares) Stock Issued During Period, Shares, New Issues Shares, Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Finished goods Inventory, Finished Goods, Gross Document Transition Report Document Transition Report Weighted-average exercise price of stock options outstanding (in dollars per share) Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,333,074 and 61,307,428 shares outstanding at March 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Costs and expenses: Costs and Expenses [Abstract] Unrecognized compensation expense recognition period (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Annual Fixed Payments Total Annual Fixed Payments Total Annual Fixed Payments Stock-based compensation expense Share-based Payment Arrangement, Expense Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Entity Emerging Growth Company Entity Emerging Growth Company Weighted- Average Remaining Contractual Term, Exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Entity Current Reporting Status Entity Current Reporting Status Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] I-Mab I-Mab Biopharma [Member] I-Mab Biopharma Valuation Assumptions Using the Black-Scholes Option-Pricing Model Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Number of commercialized molecules NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Counterparty Name [Axis] Counterparty Name [Axis] Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Inventory valuation reserves Inventory Valuation Reserves Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Cover [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Beginning balance (in shares) Ending balance (in shares) Shares, Issued Total costs and expenses Costs and Expenses Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Allowance for credit loss related to available-for-sale debt securities Debt Securities, Available-for-sale, Allowance for Credit Loss Current assets: Assets, Current [Abstract] Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Shares, Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Financial Instrument [Axis] Financial Instrument [Axis] Accrued expenses and other current liabilities Accrued Liabilities, Current I-Mab Biopharma Collaboration and License Agreement I-Mab Biopharma Collaboration And License Agreement [Member] I-Mab Biopharma Collaboration And License Agreement Fair Value Measurements, Recurring Basis Fair Value, Recurring [Member] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Document Quarterly Report Document Quarterly Report Statement of Cash Flows [Abstract] Revenue From Performance of the Research and Development Activities Revenue From Performance Of The Research And Development Activities [Member] Revenue From Performance Of The Research And Development Activities Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Common Stock [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Collaborative agreement transaction price CollaborativeAgreementTransactionPrice Loss from operations Operating Income (Loss) Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] General and Administrative General and Administrative Expense [Member] Entity Shell Company Entity Shell Company Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Lease liabilities Operating Lease, Liability, Current Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Zai Labs Zai Lab [Member] Zai Lab Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Money market funds Money Market Funds [Member] Revenues From License Agreements RevenuesFromLicenseAgreementsMember Revenue from government agreements RevenueFromGovernmentAgreementsMember Aggregate Intrinsic Value, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Current Fiscal Year End Date Current Fiscal Year End Date Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale 2003 Stock Incentive Plan A2003StockIncentivePlanMember Number of performance obligations Number Of Performance Obligations Opt-in fee Opt-in Fee Opt-in Fee Financial Assets Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Other income Other Nonoperating Income (Expense) Variable consideration recognized Clinical trial activities selling price amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Statement [Table] Statement [Table] License And Collaboration Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Range [Axis] Statistical Measurement [Axis] Total liabilities Liabilities Total potential value TotalPotentialValueUnderAgreement 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Award Type [Axis] Award Type [Axis] Weighted- Average Exercise Price, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate Intrinsic Value, Outstanding, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Maximum amount available for issuance, increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Total stockholders' equity Stockholders' Equity Attributable to Parent Potential annual increase in shares reserved for future issuance (in shares) CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance City Area Code City Area Code Aggregate Intrinsic Value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounts payable Increase (Decrease) in Accounts Payable and Other Operating Liabilities Stock Incentive Plan 2013 StockIncentivePlan2013Member Entity Address, City or Town Entity Address, City or Town Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Collaboration And Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term